Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00690066 · ClinicalTrials.gov registry record · Phase 2

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

A Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, sponsored by Mesoblast.

Completed
Registry status
Phase 2
Development phase
63
Enrollment target
20
Study locations

NCT00690066 is a Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus that has completed, run by Mesoblast. The registered enrollment target is 63 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00690066, a Phase 2 study of Type 1 Diabetes and Type 1 Diabetes Mellitus, has completed, sponsored by Mesoblast.

COMPLETED
Registry status
Phase 2
Development phase
63 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.

Conditions Studied

Type 1 Diabetes Type 1 Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Juvenile Diabetes

Interventions

  • DRUG Placebo
  • DRUG PROCHYMAL®

Study Locations (20)

California

  • Scripps Whittier Diabetes Institute - La Jolla
  • Stanford University - Stanford

Florida

  • University of Florida - Gainesville
  • Diabetes Research Institute - Miami

Nevada

  • Desert Endocrinology CRC - Henderson
  • Nevada Alliance Against Diabetes - Las Vegas

North Carolina

  • University of North Carolina Diabetes Care Center - Chapel Hill
  • American Health Research, Inc. - Charlotte

Ohio

  • The Lindner Clinical Trial Center - Cincinnati
  • Providence Health Partners - Center for Clinical Research - Dayton

Wisconsin

  • University of Wisconsin Health- West Clinic - Madison
  • Clinical and Transitional Science Institute - Milwaukee

Alabama

  • University of Alabama, Division of Endocrinology & Metabolism - Birmingham

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2008-06-11
Est. Completion 2011-12-19
Phase Phase 2

Sponsor

Mesoblast

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00690066

The ClinicalTrials.gov registry entry for NCT00690066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00690066 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Nevada.

Frequently Asked Questions

What is clinical trial NCT00690066 about?

NCT00690066 is a clinical study titled "PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)". The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.

What is the current status of trial NCT00690066?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2008-06-11. Estimated completion is 2011-12-19.

What conditions does trial NCT00690066 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes.

What interventions are being tested in trial NCT00690066?

The interventions under investigation include: Placebo (DRUG), PROCHYMAL® (DRUG).

Who is sponsoring clinical trial NCT00690066?

This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00690066 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes

All registered trials for this condition

Type 1 Diabetes Mellitus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.